Late-onset neutropenia following anti-CD20 therapies in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders: A report on two patients-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Late-onset neutropenia following anti-CD20 therapies in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders: A report on two patients

Published:2022 Issue: Volume:2 Page:100136
ISSN:2667-257X
Container-title:Neuroimmunology Reports
language:en
Short-container-title:Neuroimmunology Reports

Author:

Lim Christen Sheng Jie,Tye Janis Siew Noi,Tan Kevin,Yeo Tianrong^ORCID

Publisher

Elsevier BV

Reference23 articles.

1. Effectiveness of rituximab in neuromyelitis optica: a meta-analysis;Gao;BMC Neurol.,2019

2. Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial;Tahara;Lancet Neurol.,2020

3. B-Cell depletion with rituximab in relapsing-remitting multiple sclerosis;Hauser;N. Engl. J. Med.,2008

4. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis;Montalban;N. Engl. J. Med.,2017

5. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis;Hauser;N. Engl. J. Med.,2017

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Methylprednisolone/Ocrelizumab/Rituximab;Reactions Weekly;2024-07-13

2. Disease-modifying therapies and hematological disorders: a systematic review of case reports and case series;Frontiers in Neurology;2024-06-18

3. Recurrence of severe symptomatic late-onset neutropenia on ocrelizumab;Multiple Sclerosis Journal;2023-10-27

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3